Fluidigm (NASDAQ: AEMD) and Aethlon Medical (NASDAQ:AEMD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.
This table compares Fluidigm and Aethlon Medical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Fluidigm and Aethlon Medical’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Fluidigm||$101.94 million||3.08||-$60.53 million||($1.19)||-6.75|
|Aethlon Medical||$150,000.00||121.04||-$5.67 million||($0.46)||-2.22|
Aethlon Medical has lower revenue, but higher earnings than Fluidigm. Fluidigm is trading at a lower price-to-earnings ratio than Aethlon Medical, indicating that it is currently the more affordable of the two stocks.
This is a summary of current ratings and target prices for Fluidigm and Aethlon Medical, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Fluidigm presently has a consensus price target of $6.10, indicating a potential downside of 24.03%. Aethlon Medical has a consensus price target of $3.00, indicating a potential upside of 194.12%. Given Aethlon Medical’s stronger consensus rating and higher probable upside, analysts clearly believe Aethlon Medical is more favorable than Fluidigm.
Volatility and Risk
Fluidigm has a beta of 3.44, suggesting that its stock price is 244% more volatile than the S&P 500. Comparatively, Aethlon Medical has a beta of 2.04, suggesting that its stock price is 104% more volatile than the S&P 500.
Insider and Institutional Ownership
96.7% of Fluidigm shares are owned by institutional investors. Comparatively, 7.4% of Aethlon Medical shares are owned by institutional investors. 2.2% of Fluidigm shares are owned by company insiders. Comparatively, 6.6% of Aethlon Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Aethlon Medical beats Fluidigm on 8 of the 13 factors compared between the two stocks.
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell genomics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. It sells instruments and consumables, including IFCs, assays, and reagents to academic institutions, clinical research laboratories, and contract research organizations, as well as biopharmaceutical, biotechnology, and agricultural biotechnology companies. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.
About Aethlon Medical
Aethlon Medical, Inc., a medical device company, focuses on creating devices that address unmet medical needs in health and biodefense worldwide. The company is developing Aethlon Hemopurifier, a clinical-stage therapeutic device that eliminates life-threatening viruses from the circulatory system of infected individuals. It is also involved in the development of exosomal biomarkers to diagnose and monitor life-threatening disease conditions, such as cancer and neurological disorders; and a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection. The company was founded in 1991 and is based in San Diego, California.
Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.